Abstracts

1229 – The Cost-Effectiveness and Optimal Price Level of Injectable PrEP With Lenacapavir in South Africa

Background Injectable lenacapavir (LEN) has been shown to be 100% effective in protecting African women from HIV infection, but its acceptable price and cost-effectiveness is unknown. We estimated the impact of LEN compared to daily oral tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) and injectable cabotegravir (CAB) for HIV prevention in South Africa, and the threshold…

1214 – Are Sex-Specific Cutoffs Needed With a Next-Gen Urine Tenofovir Assay for Adherence Monitoring?

Background Females may require higher oral Pre-exposure Prophylaxis (PrEP) adherence to achieve equivalent therapeutic drug concentrations compared to males, suggesting the need for sex-specific cutoffs for rapid urine tenofovir (TFV) assays. We developed a next-gen urine TFV Lateral Flow Assay (LFA) without a predefined threshold to (1) determine if the quantified LFA readouts differ between females…

1230 – PURPOSE 1: Preference for Twice-Yearly Injection vs Daily Oral Pills for HIV PrEP in Cisgender Women

Background Although oral pre-exposure prophylaxis (PrEP) is effective for HIV prevention, its routine use in cisgender women remains low. Effectiveness is contingent on high adherence and persistence post initiation, which many cite as a barrier for daily oral pills. In the Phase 3 PURPOSE 1 trial, twice-yearly subcutaneous (SC) lenacapavir (LEN) was safe and 100% efficacious in…

1191 – HIV Serologic Reactivity in Persons With HIV Who Started ART During Acute/Early Stages of Infection

Background Persons with HIV (PWH) who receive antiretroviral treatment (ART) beginning in acute/early stages of infection may fail to develop antibody reactivity or revert to nonreactive levels on serological assays. Seroreactivity after prolonged viral suppression in PWH treated in acute/early stages of infection has not been previously characterized. Methods RV254 cohort study identified PWH with…

1118 – HIV Testing Barriers in Structurally Vulnerable Communities in St Louis: Best-Worst Scaling Survey

Background Significant gaps remain in ending the HIV epidemic in the US, calling for the need for community tailored evidence-based HIV testing strategies. Methods To understand perceptions and underlying beliefs around HIV testing, particularly among Black, queer, and young people, we conducted a Best-Worst Scaling (BWS) survey among adults (16+) in the St. Louis, Missouri region.…

1189 – Missed Opportunities: HIV Screening Deficits in Japanese Syphilis Patients

Background The rising incidence of STIs and HIV in Japan necessitates comprehensive testing strategies. This study analyzed syphilis testing, subsequent HIV screening, and HIV diagnosis patterns across age groups using a sampling dataset from the National Database of Health Insurance Claims (NDB), which represents 1% of all outpatient Japanese health insurance claims, and AIDS Surveillance…